Lupin launches nasal spray in US
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
A triple-action Formula for comprehensive respiratory relief
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Lyfius Pharma restarts operations at Penicillin-G manufacturing facility
ISG acknowledged Indegene's strengths in implementing holistic creative workflows, interoperability via robust integration with tech ecosystems
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
Star Health Insurance is modernising its claims ecosystem to be future-ready
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Subscribe To Our Newsletter & Stay Updated